Search - tctmd.com

Displaying 501 - 520 of 1588

Sort: Relevancy | Date

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Todd Neale

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Presenter: Ori Ben-Yehuda

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Presenter: Joanna Chikwe

November 05, 2021

Presentation TCT 2021

FFR REACT: A Randomized Trial of FFR-Guided PCI Optimization by IVUS Versus No Optimization

Presenter: Joost Daemen

November 05, 2021

Presentation TCT 2021

The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Clinical Trials Status Update

Presenter: David E. Kandzari

November 04, 2021

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

Presentation TCT 2021

Triluminate Registry: Lessons Learned for TEER Trial Design

Presenter: Georg Nickenig

November 04, 2021

Presentation TCT 2021

Pragmatic Clinical Trials: The Future is Now?

Presenter: Sreekanth Vemulapalli

November 04, 2021

News Conference News TCT 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

Caitlin E. Cox

November 04, 2021

Presentation TCT 2021

iFR-SWEDEHEART: Five-Year Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PCI

Presenter: Matthias Götberg

November 04, 2021

Presentation TCT 2021

Adapting Clinical Trials to a Black Swan Event, from Industry Perspective

Presenter: Sandeep Brar

November 04, 2021

Presentation TCT 2021

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

Presenter: Ajay Kirtane

November 04, 2021

Presentation TCT 2021

Adapting Clinical Trials to a Black Swan Event, from the FDA Perspective

Presenter: Andrew Farb

November 04, 2021

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

Todd Neale

November 04, 2021

Presentation TCT 2021

EROSION III: A Randomized Trial of OCT-Guided Intervention in STEMI Patients With Early Infarct Artery Patency

Presenter: Haibo Jia

November 04, 2021

News Conference News TCT 2021

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

Shelley Wood

November 04, 2021

Presentation TCT 2021

SUGAR: A Randomized Trial of Amphilimus-eluting Stents and Zotarolimus-eluting Stents in Patients With Diabetes

Presenter: Rafael Romaguera

November 04, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

Presentation TCT 2021

FAVOR III China: A Sham-Controlled Randomized Trial Comparing QFR-Guided and Angiography-Guided PCI

Presenter: Bo Xu

November 04, 2021

Advertisement

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

FFR REACT: A Randomized Trial of FFR-Guided PCI Optimization by IVUS Versus No Optimization

The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Clinical Trials Status Update

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Triluminate Registry: Lessons Learned for TEER Trial Design

Pragmatic Clinical Trials: The Future is Now?

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

iFR-SWEDEHEART: Five-Year Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PCI

Adapting Clinical Trials to a Black Swan Event, from Industry Perspective

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

Adapting Clinical Trials to a Black Swan Event, from the FDA Perspective

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

EROSION III: A Randomized Trial of OCT-Guided Intervention in STEMI Patients With Early Infarct Artery Patency

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

SUGAR: A Randomized Trial of Amphilimus-eluting Stents and Zotarolimus-eluting Stents in Patients With Diabetes

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FAVOR III China: A Sham-Controlled Randomized Trial Comparing QFR-Guided and Angiography-Guided PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content